[ad_1]
Article content material
OTTAWA, Ontario — Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Firm”), a life sciences company centered on creating and commercializing merchandise for livestock, companion animal and human purposes that safely enhances feed consumption and helps immune perform, thereby supporting basic well being and efficiency, in the present day introduced the outcomes of its annual basic assembly of shareholders held on April 19, 2023.
On the Firm’s AGM, shareholders voted to assist all the resolutions that got here earlier than the assembly. The resolutions included the election of administrators and the reappointment of McGovern Hurley LLP as Avivagen’s auditor.
Commercial 2
Article content material
Article content material
The voting ends in respect of the election of administrators are detailed beneath:
|
Nominee |
% Of Votes Forged At The Assembly |
|
Kym Anthony |
51.2% |
|
Graham Burton |
93.4% |
|
David Hankinson |
94.3% |
|
Paul Mesburis |
61.8% |
Leaving the Avivagen board are Jeffrey Kraws and Aubrey Dan, every of whom opted to not stand for reelection on the AGM. Avivagen and its board of administrators thank every of Mr. Kraws and Mr. Dan for his or her service to the Firm and want them one of the best.
David Hankinson has been appointed as Chair of the board of administrators to exchange Mr. Kraws and Kym Anthony has been appointed Vice-Chair of the board.
About Avivagen
Avivagen is a life sciences company centered on creating and commercializing merchandise for livestock, companion animal and human purposes. By unlocking an ignored side of β-carotene exercise, a path has been opened to securely and economically assist immune perform, thereby selling basic well being and efficiency in animals. Avivagen is a public company traded on the TSX Enterprise and OTCQB® Enterprise Market exchanges beneath the symbols VIV and VIVXF, and is headquartered in Ottawa, Canada, based mostly in partnership amenities of the Nationwide Analysis Council of Canada and Charlottetown, Prince Edward Island. For extra data, go to www.avivagen.com. The contents of the web site are expressly not included by reference on this press launch.
About OxC-beta™ Expertise and OxC-beta™ Livestock
Avivagen’s OxC-beta™ expertise is derived from Avivagen discoveries about β-carotene and different carotenoids, compounds that give sure fruit and veggies their shiny colors. Via assist of immune perform the expertise gives a non-antibiotic technique of selling well being and development. OxC-beta™ Livestock is a proprietary product proven to be an efficient and financial various to the antibiotics generally added to livestock feeds. The product is presently obtainable on the market in the US, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia.
Avivagen’s OxC-beta™ Livestock product is secure, efficient and will fulfill the worldwide mandate to take away all in-feed antibiotics as development promoters. Quite a few worldwide livestock trials with poultry and swine utilizing OxC-beta™ Livestock have confirmed that the product performs in addition to, and, generally, in some facets, higher than in-feed antibiotics.
Article content material
Commercial 3
Article content material
Ahead Wanting Statements
This information launch consists of sure forward-looking statements which might be based mostly upon the present expectations of administration. Ahead-looking statements contain dangers and uncertainties related to the enterprise of Avivagen Inc. and the surroundings during which the enterprise operates. Any statements contained herein that aren’t statements of historic details could also be deemed to be forward-looking, together with these recognized by the expressions “goal”, “anticipate”, “seem”, “consider”, “think about”, “may”, “estimate”, “count on”, “if”, “intend”, “purpose”, “hope”, “seemingly”, “might”, “plan”, “probably”, “probably”, “pursue”, “appear”, “ought to”, “whether or not”, “will”, “would” and comparable expressions.
Statements set out on this information launch regarding the market alternatives for the Firm, the expectation that Avivagen’s present place positions it for future development, expectation as to additional adoption of or orders for the Firm’s merchandise, the chance that trials underway may result in further orders sooner or later and the chance for OxC-beta™ Livestock to exchange antibiotics in livestock feeds as development promoters are forward-looking statements. These forward-looking statements are topic to various dangers and uncertainties that would trigger precise outcomes or occasions to vary materially from present expectations. As an illustration, unexpected components may restrict the expansion of the Firm and the adoption of its merchandise, prospects are beneath no obligation to make further orders and should not order growing portions of the Firm’s merchandise, partnerships is probably not as profitable as hoped, trials is probably not profitable or might not result in further adoption of the Firm’s merchandise, Avivagen’s merchandise might not achieve market acceptance or regulatory approval in new jurisdictions or for brand spanking new purposes and is probably not broadly accepted as a alternative for antibiotics as development promoters in livestock feeds, all of which may happen on account of many components, lots of that are outdoors of Avivagen’s management. Readers are referred to the danger components related to the enterprise of Avivagen set out in Avivagen’s most up-to-date administration’s dialogue and evaluation of economic situation obtainable at www.SEDAR.com. Besides as required by legislation, Avivagen assumes no obligation to replace the forward-looking statements, or to replace the explanation why precise outcomes may differ from these mirrored within the forward-looking statements.
Commercial 4
Article content material
Neither TSX Enterprise Change nor its Regulation Providers Supplier (as that time period is outlined within the insurance policies of the TSX Enterprise Change) accepts duty for the adequacy or accuracy of this launch.
Copyright © 2022 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.
View supply model on businesswire.com: https://www.businesswire.com/news/home/20230419006003/en/
Contacts
For extra data:
Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Cellphone: 416-540-0733
E-mail: d.basek@avivagen.com
Kym Anthony
Chief Govt Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Workplace
Cellphone: 613-949-8164
Web site: www.avivagen.com
#distro
[ad_2]
Source link
Feedback
Postmedia is dedicated to sustaining a vigorous however civil discussion board for dialogue and encourage all readers to share their views on our articles. Feedback might take as much as an hour for moderation earlier than showing on the location. We ask you to maintain your feedback related and respectful. We now have enabled e-mail notifications—you’ll now obtain an e-mail in case you obtain a reply to your remark, there’s an replace to a remark thread you observe or if a person you observe feedback. Go to our Community Guidelines for extra data and particulars on methods to regulate your email settings.
Be part of the Dialog